Observational studyJournal of molecular medicine (Berlin, Germany)2020

A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.

Andrea Nicolini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.